Intranasal Oxytocin for the Treatment of Pain Associated with Interstitial Cystitis
Annual rept. 1 Sep 2013-31 Aug 2014
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
The purpose of this study is to evaluate the efficacy of intranasal oxytocin on bladder nociception in a cohort of patients with interstitial cystitis IC. We hypothesize that patients with IC are more likely to experience treatment responses as defined by global response assessment GRA scores when they receive intranasal oxytocin as opposed to when they receive intranasal saline. Secondary outcome measures include a verbal pain report VPR 0-10 with 0 being no pain and 10 being the worst possible pain, a verbal anxiety report VAR 0-10 with 0 being no anxiety and 10 being the worst possible anxiety, number of voids since last contact with an investigator, and interim medications used for pain control or anxiety. Compared to saline administration intranasal oxytocin did significantly decrease anxiety reports from participants. While the difference in pain ratings between the two treatments is not statistically significant, there does also appear to be a small effect of oxytocin at reducing pain.
- Anatomy and Physiology
- Medicine and Medical Research